Amendment: SEC Form SCHEDULE 13D/A filed by Pluri Inc.

Item 4 of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D relating to CHL, CHLP, Plantae and Mr. Weinstein is incorporated by reference.

Item 5(a) of the Schedule 13D is hereby amended and restated as follows: The information contained on the cover pages of this Schedule 13D is incorporated by reference. Based on 10,774,666 Common Shares issued and outstanding as of April 23, 2026 (as confirmed by the Issuer), the Reporting Persons beneficially own an aggregate of 3,794,897 shares of Common Stock, representing approximately 34.73% of the outstanding Common Stock. The breakdown of beneficial ownership among the Reporting Persons is as follows: CHL CHL beneficially owns 2,018,014 shares, consisting of 1,933,415 common shares directly held (comprising 407,809 PIPE shares, 1,002,169 shares from exercise of pre-funded warrants, and 523,437 Kokomodo consideration shares) and warrants to purchase 84,599 common shares. CHL's warrants are not subject to a beneficial ownership limitation (the original 19.99% limitation having been removed upon shareholder approval on June 30, 2025). CHLP CHLP beneficially owns 1,317,897 shares, consisting of 1,250,000 common shares directly held and warrants to purchase 110,000 common shares (being the maximum number of warrant shares currently exercisable without exceeding the 35% Beneficial Ownership Limitation applicable to each of CHLP's three warrant instruments). CHLP holds warrants to purchase an aggregate of 1,250,000 common shares, but only 110,000 of such warrant shares are included in CHLP's beneficial ownership because CHLP does not have the right to acquire the remaining 1,182,103 warrant shares -- the Beneficial Ownership Limitation in each warrant instrument contractually prohibits exercise to the extent it would cause the Reporting Persons' aggregate beneficial ownership to exceed 35% of outstanding Common Shares. See "Beneficial Ownership Limitation" below for the detailed calculation. CHLP holds warrants to purchase an aggregate of 1,250,000 Common Shares under three separate warrant instruments, as follows: (i) Warrants to purchase 625,000 Common Shares, issued pursuant to the Securities Purchase Agreement dated December 8, 2025, at an exercise price of $4.25 per share, exercisable immediately and expiring on June 30, 2026; (ii) Warrants to purchase 312,500 Common Shares, issued pursuant to the Securities Purchase Agreement dated March 24, 2026, at an exercise price of $4.25 per share, exercisable immediately and expiring approximately September 30, 2027 (18 months from the March 31, 2026 issuance date); and (iii) Warrants to purchase 312,500 Common Shares, issued pursuant to the Securities Purchase Agreement dated March 24, 2026, at an exercise price of $4.25 per share, exercisable immediately and expiring on October 21, 2027 (18 months from the April 21, 2026 issuance date). Each warrant instrument contains a beneficial ownership limitation provision (each, a "Beneficial Ownership Limitation") that independently restricts the exercise of that particular warrant. Specifically, each warrant provides that CHLP may not exercise such warrant to the extent that, after giving effect to the issuance of the warrant shares upon such exercise, the Holder, together with its Affiliates and any other Persons whose beneficial ownership of Common Shares would or could be aggregated with the Holder's for purposes of Section 13(d) of the Exchange Act (collectively, the "Attribution Parties"), would beneficially own in excess of 35% of the number of Common Shares outstanding immediately after giving effect to such issuance. Each warrant instrument's Beneficial Ownership Limitation is evaluated independently at the time CHLP submits a Notice of Exercise under that particular warrant. At the time of each exercise, the numerator of the ownership calculation includes all Common Shares then held by the Holder, its Affiliates and Attribution Parties, plus the warrant shares to be issued in that particular exercise. The numerator excludes (a) the remaining unexercised portion of the warrant being exercised and (b) any other securities of the Company subject to an analogous beneficial ownership limitation (i.e., the other CHLP warrant instruments, which each contain their own 35% Beneficial Ownership Limitation). The denominator is the total number of Common Shares outstanding immediately after giving effect to the issuance of the warrant shares in that particular exercise. Plantae Plantae beneficially owns 452,702 shares, consisting of 452,702 common shares directly held. Mr. Weinstein Mr. Weinstein beneficially owns 3,794,897 shares in the aggregate, consisting of: (i) 6,284 shares held directly (5,643 vested RSU shares plus 641 RSUs vesting within 60 days on May 25, 2026); (ii) 2,018,014 shares through CHL (Mr. Weinstein indirectly owns 100% of CHL); (iii) 1,317,897 shares through CHLP (beneficially owned by Mr. Weinstein); and (iv) 452,702 shares through Plantae (Mr. Weinstein indirectly owns approximately 78% of Plantae through CHL). Mr. Weinstein disclaims beneficial ownership of securities held by Plantae except to the extent of his pecuniary interest therein.

Item 5(b) of the Schedule 13D is hereby amended and restated as follows: In the aggregate, the Reporting Persons beneficially own 3,794,897 Common Shares representing approximately 34.98% of the issued and outstanding shares of the Issuer. Each of the Reporting Persons expressly disclaims beneficial ownership with respect to any shares of Common Stock of the Issuer, other than the Common Stock of the Issuer owned of record by such Reporting Person.

Item 5(c) of the Schedule 13D is amended and supplemented as follows: The information contained in Item 4 of this Schedule 13D is incorporated by reference.

1. Securities Purchase Agreement dated January 23, 2025: Between the Issuer and CHL, pursuant to which CHL acquired common shares, pre-funded warrants, and common warrants. 2. Asset Purchase Agreement (Kokomodo): Pursuant to which CHL received 523,437 and Plantae received 452,702 consideration shares. 3. Securities Purchase Agreement dated December 8, 2025: Between the Issuer and CHLP, for 625,000 common shares and warrants to purchase 625,000 common shares. Closing occurred on December 30, 2025. 4. Securities Purchase Agreement dated March 24, 2026: Between the Issuer and CHLP, for 625,000 common shares and warrants to purchase 625,000 common shares. Closed in two tranches on March 31, 2026 and April 21, 2026. 5. Common Warrants: CHL holds warrants exercisable for 84,599 shares at $5.568, expiring February 5, 2028 (not subject to a beneficial ownership limitation). CHLP holds warrants exercisable for up to 1,250,000 shares at $4.25 under three separate warrant instruments: (i) 625,000 warrants expiring June 30, 2026 (December 2025 SPA); (ii) 312,500 warrants expiring approximately September 30, 2027 (March 2026 SPA, first closing); and (iii) 312,500 warrants expiring October 21, 2027 (March 2026 SPA, second closing). Each CHLP warrant is subject to a 35% beneficial ownership limitation. See Item 5(a) for a detailed description of the limitation and its effect on reported beneficial ownership. 6. Restricted Stock Unit Award Agreements: Mr. Weinstein holds RSU awards under the Issuer's 2016 Equity Compensation Plan (10,250 RSUs granted February 25, 2025) and 2019 Equity Compensation Plan (519 RSUs granted December 1, 2025). 7. Joint Filing Agreement: The Reporting Persons have entered into a joint filing agreement, filed as an exhibit hereto.

Item 7 is supplemented with the following exhibits: Exhibit 1: Joint Filing Agreement sec.gov/Archives/edgar/data/1158780/000121390026015550/ea0275848-10q_pluri.htm sec.gov/Archives/edgar/data/1158780/000121390026035110/ea0283653-8k_pluri.htm file:///N:/EDGAR%20FILES/1-PreSub/ea0256130/ea0256130-01/proof.